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Genetic and chemical inhibition of IRF5 suppresses
pre-existing mouse lupus-like disease
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The transcription factor IRF5 has been implicated as a therapeutic target for the autoimmune
disease systemic lupus erythematosus (SLE). However, IRF5 activation status during the
disease course and the effects of IRF5 inhibition after disease onset are unclear. Here, we
show that SLE patients in both the active and remission phase have aberrant activation of
IRF5 and interferon-stimulated genes. Partial inhibition of IRF5 is superior to full inhibition of
type I interferon signaling in suppressing disease in a mouse model of SLE, possibly due to the
function of IRF5 in oxidative phosphorylation. We further demonstrate that inhibition of IRF5
via conditional Irf5 deletion and a newly developed small-molecule inhibitor of IRF5 after
disease onset suppresses disease progression and is effective for maintenance of remission in
mice. These results suggest that IRF5 inhibition might overcome the limitations of current SLE
therapies, thus promoting drug discovery research on IRF5 inhibitors.
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Systemic lupus erythematosus (SLE) is an intractable chronicautoimmune disease characterized by a breakdown ofimmune tolerance to nuclear self-antigens1,2. The patients
are primarily females of reproductive age and manifest the pro-
duction of autoantibodies, such as those against double-stranded
DNA (dsDNA) and ribonucleoproteins. Immune complexes
formed by these autoantibodies are deposited in various organs
and induce recurrent inflammatory lesions. There are genetic,
environmental (infection and sunburn), and hormonal (estrogen)
factors that influence the disease development3.
Current standard therapies for SLE include glucocorticoster-
oids, antimalarial drugs, and immunosuppressants4,5. The most
recently approved agent is a monoclonal antibody against B cell-
activating factor (BAFF)6. Owing to these therapies, the 10-year
survival rate has improved from 63 to 91% in the past 50 years7.
However, SLE patients still have unmet medical needs8,9. These
problems include the paucity of treatment options for poor
responders with intractable organ disease, low health-related
quality of life, comorbidities, drug adverse effects such as
opportunistic infections and osteoporosis, and a shorter life span.
In the case of a relapse, high doses of glucocorticosteroids or
immunosuppressants are often required, and therefore
relapsing–remitting inflammation results in not only further tis-
sue damage but also severer adverse effects of the drugs.
One of the highly anticipated new drugs currently in clinical
trials is an anti-type I interferon (IFN) receptor monoclonal
antibody that blocks the action of type I IFNs (IFN-α and -β)9.
SLE patients display high expression of IFN-stimulated genes
(ISGs) called the IFN signature10, and animal experiments have
revealed that blocking of type I IFN signaling inhibits SLE-like
symptoms11–13. Recently, it was announced that phase III trials of
anifrolumab, an antagonist antibody targeting anti-IFN-α and -β
receptor subunit 1 (IFNAR1), reached their primary endpoint14.
The percentage of responders was higher in the anifrolumab
group (47.8%) than in the placebo group (31.5%). Nevertheless,
the annualized relapse rate was still as high as 43% in the ani-
frolumab group. Thus, the development of additional therapies
other than (or in addition to) blocking of type I IFN signaling is
desirable.
The main focus of SLE research has been the adaptive immune
system, e.g., aberrant activation of autoreactive T and B cells.
Currently, however, it is acknowledged that the innate immune
system, which initiates inflammation and actuates the adaptive
immune system, also significantly contributes to the disease
pathogenesis15,16. Indeed, multiple genome-wide association
studies have identified IRF5 as one of the genes whose genetic
variants are highly associated with SLE risk17,18; IRF5 encodes a
transcription factor called IFN regulatory factor 5, which posi-
tively regulates endosomal Toll-like receptor (TLR)-mediated,
myeloid differentiation primary response protein 88 (MyD88)-
dependent innate immune responses19,20. Stimulation of TLR7,
TLR8, or TLR9 activates IRF5 via its phosphorylation and nuclear
translocation, leading to the induction of type I IFN and
inflammatory cytokine genes21,22. IRF5 has been shown to be
activated in monocytes of most SLE patients, and its expression is
further induced by type I IFNs and estrogen23,24. Moreover, we
and other laboratories have demonstrated that even a half IRF5
deficiency prevents disease onset in various mouse models of
SLE25–28. IRF5 functions in multiple cell types involved in SLE
pathogenesis, for example, conventional dendritic cells (cDCs),
plasmacytoid DCs (pDCs), follicular DCs, monocytes, and B
cells17,21. Therefore, IRF5 appears to be a key factor of various
steps of SLE pathogenesis, despite the heterogeneous nature of the
disease.
In this study, we address (1) the activation status of IRF5 in the
course of human SLE, (2) whether IRF5 functions other than in
the induction of type I IFNs, and (3) the effects of IRF5 inhibition
on the SLE pathogenesis after the disease onset. We analyze SLE
patients and mouse SLE models and develop a prototypical small-
molecule compound that limits IRF5 activation. Our results
support the idea that IRF5 inhibition overcomes the limitations of
current therapies for SLE and should justify drug discovery
research on IRF5 inhibitors.
Results
IRF5 is activated in both active- and remission-phase SLE (AP-
SLE and RP-SLE, respectively) patients. To find out whether the
activation status of IRF5 has relevance to SLE disease activity, we
assessed IRF5 nuclear translocation in immune cells isolated from
peripheral blood of SLE patients (Fig. 1a, Supplementary
Fig. 1a–c, and Supplementary Table 1). Our method, which
evaluates the IRF5 nuclear/cytoplasmic ratio, clearly distinguished
IRF5 undergoing nuclear translocation (Fig. 1a and Supplemen-
tary Fig. 1a–c). Consistent with another report24, the proportion
of cells in which IRF5 was translocated into the nucleus was
higher in monocytes from SLE patients than those from healthy
donors (Fig. 1b and Supplementary Fig. 2). The proportion of
individuals displaying IRF5 nuclear translocation in ≥5% of
monocytes was 4% in healthy donors and 52% in SLE patients.
Although the difference was modest, a similar tendency was
observed in pDCs and cDCs but not B cells (Supplementary
Fig. 3a). As expected from other studies29,30, the degree of IRF5
activation in monocytes correlated with expression levels of ISGs
such as OAS1, IFI27, and MX1 in peripheral blood (Fig. 1c and
Supplementary Fig. 3b).
We then subdivided the patients into two groups according to
the SLE disease activity index (SLEDAI) score: AP-SLE (SLEDAI-
2K ≥ 5) and RP-SLE (SLEDAI-2K < 5) (Fig. 1d and Supplemen-
tary Table 1). The proportion of monocytes featuring IRF5
nuclear translocation and the expression levels of ISGs were
higher in AP-SLE than in healthy controls, and furthermore, both
remained higher even in RP-SLE than in the controls (Fig. 1e, f
and Supplementary Fig. 3c). We also calculated the strength of
aberrant IRF5 nuclear translocation by summing the nuclear/
cytosolic ratios exceeding the control levels. Still, the degree of
IRF5 translocation was largely unchanged between AP-SLE and
RP-SLE (Supplementary Fig. 3d). Analysis of publicly available
gene expression data from individual SLE patients31 revealed that
ISG expression in peripheral blood was high despite a sign of
glucocorticosteroid administration, e.g., glucocorticoid-induced
leucine zipper (GILZ) expression (Supplementary Fig. 3e). This
finding suggested that the persistently high ISG expression after
standard therapies is not limited to our study cohort. In RP-SLE,
the activation status of IRF5 nuclear translocation in monocytes
correlated with serum concentration of residual autoantibodies
(Fig. 1g and Supplementary Fig. 3f).
Moreover, regardless of the administration of prednisolone
(PSL), hydroxychloroquine (HCQ), or mycophenolate mofetil
(MMF), the percentage of monocytes with IRF5 nuclear
translocation as well as the expression levels of ISGs remained
high (Fig. 1h, i and Supplementary Fig. 3g, h). These results
suggested that the current standard therapies are unable to
repress aberrant IRF5 activation and ISG expression in SLE
patients. Indeed, high doses of representative drugs currently used
as standard SLE treatments failed to inhibit IRF5 phosphoryla-
tion, another hallmark of its activation, as detected by a phospho-
IRF5-specific monoclonal antibody in peripheral blood mono-
nuclear cells (PBMCs) stimulated in vitro with R-848, which is a
ligand of TLR7 and TLR8 (Fig. 1j; the validation of antibody
specificity is shown in Supplementary Fig. 4a). In these
experiments, TPCA-1, an inhibitor of the inhibitor of nuclear
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factor κ-B (NF-κB) kinase subunit β (IKKβ; the kinase that
activates NF-κB and IRF5)21,22 served as a positive control.
TPCA-1 inhibited nuclear translocation of both IRF5 and NF-κB
p65 in monocytes and pDCs as expected (Supplementary Fig. 4b,
c), indicating that IKKβ inhibitors are not suitable for IRF5-
specific suppression.
Targeting IFNAR1 is not sufficient to suppress disease in a
Lyn-deficient mouse SLE model. The similar dynamics of IRF5
activation and ISG expression in SLE patients prompted us to
investigate whether the inhibition of IRF5 exerts only the action
that equals the effect of inhibition of type I IFNs. For this purpose,
we used Lyn-deficient (Lyn−/−) mice as a mouse SLE model. Lyn
deficiency causes IRF5 hyperactivation in the TLR-MyD88 path-
way, thereby causing overproduction of cytokines including type I
IFNs, and that even a half IRF5 deficiency strongly suppresses the
development of SLE-like disease25. The production of anti-dsDNA
immunoglobulin G (IgG) observed in Lyn−/− mice was almost
completely inhibited by either monoallelic or biallelic deletion of
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Fig. 1 Activation status of IRF5 in human SLE. a Evaluation of IRF5 activation by nuclear translocation (NT). Fluorescent images of monocytes (Mo),
stained with control IgG (left) or an anti-IRF5 antibody (middle and right) and then with a fluorochrome-conjugated secondary antibody (yellow), were
captured by confocal microscopy. Nuclei were stained with DAPI (cyan). Representative images of cells with or without IRF5 NT, obtained from two of the
SLE patients and one of the healthy control (HC) donors, respectively, analyzed in b are shown. Scale bars represent 5 μm. b IRF5 hyperactivation in SLE-
associated monocytes. The IRF5 NT was defined as the nuclear/cytosolic IRF5 ratio of >1.5× most frequent ratio from the same sample containing 75–100
cells (see “Methods”). The proportion of monocytes featuring IRF5 NT in HC donors and SLE patients. c Correlation between IRF5 NT and ISG expression.
A scatterplot of IRF5 NT prevalence among monocytes and the OAS1mRNA level in peripheral blood are shown. d–f Persistence of aberrant IRF5 activation
and ISG expression in remission-phase (RP)-SLE. Active-phase (AP)- and RP-SLE were defined as the SLEDAI-2K≥ 5 and <5, respectively (d). The
percentage of monocytes with IRF5 NT (e) and the OAS1 mRNA level in peripheral blood (f) in AP- and RP-SLE were analyzed. g Correlation between IRF5
NT and the anti-dsDNA antibody level in RP-SLE. A scatterplot of IRF5 NT prevalence among monocytes and serum anti-dsDNA antibody concentration in
AP- and RP-SLE are presented. h, i Persistence of aberrant IRF5 activation and ISG expression after the standard therapy. Percentages of monocytes
featuring IRF5 NT (h) and OAS1 mRNA levels in peripheral blood (i) from SLE patients treated or not treated with PSL were analyzed. j Effects of standard-
of-care drugs on IRF5 activation. PBMCs from a HC donor were pretreated with 1.5 μM PSL, 3 μM HCQ, 60 μM mycophenolic acid (MPA), or 1 μM TPCA-1
(positive control) for 30min and then stimulated with 3 μM R-848 for 60 or 120min. The cell lysates were analyzed by a capillary-based immunoassay
with antibodies against phosphorylated IRF5 (phospho-IRF5), total IRF5, and GAPDH as a loading control. Representative data from two independent
experiments are depicted. HC: n= 25, SLE: n= 44 (b, c), AP-SLE: n= 27 (d, f), or 18 (e, g), RP-SLE: n= 31 (d, f) or 26 (e, g), PSL (−): n= 8 (h) or 13 (i),
PSL (+): n= 36 (h) or 45 (i). Horizontal bars (b, d–f, h, i) represent median with interquartile range. Dashed lines (e, f, h, i) indicate the median of HC data.
***P < 0.001, ns: not significant (two-sided Mann–Whitney U test). Two-sided Spearman’s rank correlation coefficients (rs) and P value were used to
assess the correlation (c, g).
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hand, the autoantibody formation was not suppressed either by
monoallelic or biallelic deletion of Ifnar1 (Lyn−/−Ifnar1+/− or
Lyn−/−Ifnar1−/−; Fig. 2a). Splenomegaly, glomerulonephritis, and
IgG deposits were also much more significantly weaker in the Lyn
−/−Irf5+/− strain and Lyn−/−Irf5−/− strain compared to strains
Lyn−/−Ifnar1+/− and Lyn−/−Ifnar1−/− (Fig. 2b–f). Similar results
were obtained for the activation status of innate and adaptive
immune cells, particularly, the expression of CD80 and CD69 on
cDC2s and CD4+ T cells, respectively (Supplementary Figs. 5a, b
and 6a, b). Our results are in agreement with the findings obtained
in FcγRIIB−/−Yaa and FcγRIIB−/− mouse models of SLE27. These
results suggested that even partial inhibition of IRF5 is superior to
the full inhibition of type I IFN signaling in terms of suppressing

































































































































































Gene set NES q-value NES q-value
IFN- response 3.0 1.8
IFN- response 2.7 1.9
Inflammatory response 1.8 1.9
IL6-JAK-STAT3 signaling 1.8 2.2
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IRF5 regulates oxidative phosphorylation (OXPHOS) in a Lyn-
deficient mouse SLE model. To clarify a role of IRF5 other than
the induction of type I IFNs in SLE pathogenesis, we analyzed the
peripheral blood transcriptome of SLE patients, which is available
in a public database31, and the peripheral blood transcriptome of
Lyn-deficient mice with concomitant Ifnar1 or Irf5 deficiency.
Gene set enrichment analysis (GSEA) revealed that seven gene
sets, including IFN-α response and OXPHOS gene sets, were
significantly upregulated both in SLE patients and Lyn-deficient
mice compared to healthy donors and wild-type (WT) mice,
respectively (Fig. 2g and Supplementary Fig. 6c).
To find the gene sets regulated specifically by IRF5 in the SLE
model, we compared Lyn−/−Ifnar1−/− mice with Lyn−/−Irf5−/−
mice. We identified only one such gene set, related to OXPHOS,
with expression significantly higher in Lyn−/−Ifnar1−/− mice
than in Lyn−/−Irf5−/− mice (Fig. 2h, i). This gene set includes
genes encoding components of OXPHOS complexes, such as
NADH dehydrogenases, cytochrome c oxidase, and reductase,
and ATPases (Fig. 2j). The expression of these genes was found to
be strongly downregulated in both Lyn−/−Irf5+/− and Lyn−/−
Irf5−/− mice (to the WT levels) but were almost unchanged in
Lyn−/−Ifnar1−/− mice (Fig. 2k). The elevated expression of IFN-
α response genes, most of which are ISGs, was reversed in the
Lyn−/−Ifnar1−/−, Lyn−/−Irf5+/−, and Lyn−/−Irf5−/− strains,
with profound suppression in the Lyn−/−Ifnar1−/− strain, which
completely lacks type I IFN signaling (Fig. 2h and Supplementary
Fig. 6d–f).
To confirm the GSEA results of OXPHOS genes, using
tetramethylrhodamine methyl ester (TMRM) as a probe, we
measured the mitochondrial membrane potential, which reflects
the process of OXPHOS and is therefore a key indicator of
mitochondrial activity (Supplementary Fig. 7a, b). Among the
various cell types tested, Ly6C− monocytes and pDCs showed
higher TMRM signals in Lyn−/− mice than in WT mice. The
upregulation of TMRM signals in these Lyn−/− cell types was
significantly suppressed by IRF5 deficiency but not by IFNAR1
deficiency, indicating the role for IRF5. Yet, it is still possible that
IRF5 regulates OXPHOS genes in certain subpopulations within
other cell types as well. These results suggested that IRF5 is
uniquely involved in the induction of OXPHOS genes, causing
mitochondrial dysregulation in SLE.
Conditional Irf5 ablation reduces disease in a Lyn-deficient
mouse SLE model. The above results, together with previous
results obtained from various mouse SLE models17,25, imply that
IRF5 inhibition may serve as an effective therapy for SLE.
Nonetheless, these experiments, in which SLE model mice were
crossed with IRF5 straight knockout (KO) mice, proved only the
prophylactic effects of IRF5 downregulation because IRF5 was
deficient before the onset of SLE. To investigate whether IRF5
inhibition is useful for the treatment of the disease after the onset,
we first utilized a conditional KO (cKO) of Irf5 by means of the
tamoxifen (TAM)-inducible Cre-loxP (floxed [fl] Irf5 and CreER
transgenic) system in Lyn-deficient mice. Serum concentration of
anti-dsDNA autoantibodies in Irf5 cKO (Lyn−/−Irf5fl/flCreER)
mice and littermate controls (Lyn−/−Irf5fl/fl) was measured every
2 weeks starting from 10 weeks of age. After the anti-dsDNA
autoantibody level exceeded 1 µg/ml, the mice were treated with
TAM once a day for 5 days by oral gavage (Fig. 3a). Since TAM
has been reported to have a certain beneficial effect on SLE
regardless of CreER32, we used Lyn−/−Irf5fl/fl mice treated with
TAM as controls. Serum concentrations of anti-dsDNA IgGs
before the TAM treatment were comparable between strains
Lyn−/−Irf5fl/flCreER and Lyn−/−Irf5fl/fl (Fig. 3b). We confirmed
that the expression of Irf5 mRNA in peripheral blood was
effectively eliminated by TAM treatment of Lyn−/−Irf5fl/flCreER
mice (Fig. 3c). The high expression of ISGs, namely, Oasl2, Ifit1,
and Isg15, in Lyn−/−Irf5fl/flCreER mice was markedly reduced by
TAM treatment to the levels comparable to those in WT mice,
whereas it persisted in Lyn−/−Irf5fl/fl mice (Fig. 3d and Supple-
mentary Fig. 8a). These results indicated that the conditional
deletion of Irf5 after the appearance of autoantibodies can
attenuate the IFN signature in Lyn-deficient mice.
While the anti-dsDNA autoantibody level escalated in
Lyn−/−Irf5fl/fl mice over time, this exacerbation was strongly
attenuated by TAM treatment in Lyn−/−Irf5fl/flCreER mice
(Fig. 3e). IRF5 has been shown to promote the IgG2c class
switch33,34. However, total IgG, IgG1, and IgG2c levels in serum
samples were mostly comparable between these two strains
(Supplementary Fig. 8b), suggesting that the conditional Irf5
deletion preferentially inhibits the production of autoantibodies.
Spleen weight measured at 24–28 weeks after the TAM treatment
was significantly lower in Lyn−/−Irf5fl/flCreER mice than in
Lyn−/−Irf5fl/fl mice (Fig. 3f). Similar results were obtained for
glomerulonephritis, IgG deposits in kidneys, and the activation
status of innate and adaptive immune cells (expression of CD80
and CD69 on cDC2s and CD4+ T cells, respectively) (Fig. 3g–i
and Supplementary Fig. 8c, d). On the other hand, the effect of
conditional Irf5 ablation after disease onset in Lyn–/– mice on the
Fig. 2 Superiority of IRF5 over IFNAR1 in suppressing SLE-like disease development. a Autoantibody formation. Serum concentration of an anti-dsDNA
antibody in WT (n= 12), Lyn−/− (n= 16), Lyn−/−Ifnar1+/− (n= 11), Lyn−/−Ifnar1−/− (n= 16), Lyn−/−Irf5+/− (n= 16), and Lyn−/−Irf5−/− (n= 14) female
and male mice at 22–24 weeks of age was measured by ELISA. b, c Splenomegaly. Representative image (b) and weight data (c) of the spleens of WT (n=
17), Lyn−/− (n= 18), Lyn−/−Ifnar1+/− (n= 11), Lyn−/−Ifnar1−/− (n= 18), Lyn−/−Irf5+/− (n= 12), and Lyn−/−Irf5−/− (n= 6) mice at 22–24 weeks of age.
Scale bar represents 10mm (b). The circles and diamonds denote the female and male mice, respectively (c). d–f Kidney pathology and IgG deposition.
d Representative images of periodic acid-Schiff (top) and hematoxylin–eosin (H&E; middle) staining, and IgG immunofluorescence (IF; bottom) of kidney
glomeruli from WT (n= 9), Lyn−/− (n= 9), Lyn−/−Ifnar1+/− (n= 6), Lyn−/−Ifnar1−/− (n= 6), Lyn−/−Irf5+/− (n= 6), and Lyn−/−Irf5−/− (n= 6) mice at
33–34 weeks of age. Scale bars denote 20 μm. e Glomerular cell proliferation in d (represented by the number of nuclei per glomerulus) was analyzed. Each
dot represents the mean nucleus counts of ten glomeruli per mouse. f Relative MFI of the IgG deposited in glomeruli in d was analyzed. Each dot represents
the relative MFI of the five glomeruli per mouse. g–k RNA-seq data from peripheral blood obtained from SLE patients and HC donors (public data) or from
WT, Lyn−/−, Lyn−/−Ifnar1−/−, Lyn−/−Irf5+/−, and Lyn−/−Irf5−/− female mice at 22–23 weeks of age (n= 4 for each genotype) were subjected to GSEA.
g Sets of genes that were significantly upregulated in both SLE patients (versus [vs] HC donors) and Lyn−/− mice (vs WT mice; false discovery rate < 0.05).
h Gene sets in g were further analyzed to extract gene sets whose expression levels were significantly different between Lyn−/−Ifnar1−/− and Lyn−/−Irf5−/−
mice (false discovery rate < 0.05). i The GSEA enrichment plot of OXPHOS genes (Lyn−/−Ifnar1−/− vs Lyn−/−Irf5−/−). NES normalized enrichment score.
j A heatmap of the expression of OXPHOS genes in the indicated genotypes. The color represents the mean fold change (FC) as compared to WT. Genes
with FC > 1.5 in Lyn−/− mice are shown. k A dot plot of the data from j (n= 36 for each genotype). Horizontal bars indicate mean ± SEM (a, c, e, f) or median
with interquartile range (k). Data in a–f were pooled from at least two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant (two-
sided Student’s t test in a, c, e, f, and two-sided Mann–Whitney U test in k).
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aberrant TMRM signals in Ly6C− monocytes and pDCs appeared
to be limited (Supplementary Fig. 8e), implying that IRF5 may be
involved in a process causing abnormal mitochondrial activity at
an early stage of SLE pathogenesis. Overall, these results support
the notion that post-disease onset inhibition of IRF5 strongly
suppresses the progression of mouse SLE.
Irf5 cKO maintains the remission of disease in Lyn-deficient
mice. We noticed that the number of long-lived plasma cells
(LLPCs), one of the key cell populations responsible for auto-
antibody secretion in SLE35,36, is higher in Lyn−/−Irf5fl/fl mice,
and this increase was not effectively attenuated by the conditional
deletion of Irf5 in Lyn−/−Irf5fl/flCreERmice treated with TAM for
a
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Fig. 3 Therapeutic effect of Irf5 ablation on pre-existing mouse SLE-like disease. a The scheme of the IRF5 cKO experiment; p.o. per os. b Concentration
of serum anti-dsDNA IgG in WT (n= 17), Lyn−/−Irf5fl/fl (n= 17), and Lyn−/−Irf5fl/flCreER (n= 14) female and male mice at 1 week before tamoxifen (TAM)
treatment (11–23 weeks of age). c, d Irf5 and ISG expression. Irf5 (c) and Oasl2 (d) mRNA levels in peripheral blood from mice in b at the indicated time
points were analyzed by RT-qPCR. e Autoantibody formation. Serum anti-dsDNA IgG concentrations in mice in b at the indicated time points were
measured by ELISA. f Spleen weight of WT (n= 17), Lyn−/−Irf5fl/fl (n= 15), and Lyn−/−Irf5fl/flCreER (n= 12) mice at 24–28 weeks after TAM treatment
(40–51 weeks of age). The circles and diamonds denote the female and male mice, respectively. g–i Kidney pathology and IgG deposition analyses as in
Fig. 2d–f. WT (n= 10 in h and 14 in i), Lyn−/−Irf5fl/fl (n= 17), and Lyn−/−Irf5fl/flCreER (n= 13) mice at age 40–51 weeks were studied. Scale bars represent
20 μm. Horizontal bars (b–f, h, i) indicate mean ± SEM. Dashed lines (b–e) denote the mean of WT mouse data. Data were compiled from seven
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided Student’s t test in b, e, f; two-sided Welch’s t test in h, i; two-sided Student’s t test
for a comparison between genotypes or the two-sided paired t test for a comparison within the same genotype in c, d).
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24–28 weeks (Fig. 4a and Supplementary Fig. 9a). We reasoned
that these LLPCs are the source of residual autoantibodies in the
TAM-treated Lyn−/−Irf5fl/flCreER mice. Although it may be dif-
ficult to achieve the cure in mouse genetic models of SLE in which
the cause of the disease—Lyn deficiency in this case—persists, we
explored therapeutic conditions to attain a better effect of IRF5
inhibition. To this end, we utilized bortezomib (BZ), a proteasome
inhibitor that has been shown to deplete LLPCs37, as a remission
induction therapy. A short-term administration of BZ (three times
in 5–7 days) to diseased Lyn–/– mice markedly diminished the
LLPC population in 1 week (Supplementary Fig. 9b). Serum anti-
dsDNA autoantibody levels also dramatically dropped in 2 weeks,
reaching a remission-like state (Supplementary Fig. 9c). None-
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Fig. 4 Maintenance of remission by the Irf5 cKO in the Lyn-deficient mouse model of SLE. a The LLPC number in bone marrow (BM; left) or in the spleen
(right) fromWT (n= 17), Lyn−/−Irf5fl/fl (n= 10), and Lyn−/−Irf5fl/flCreER (n= 12) mice at 24–28 weeks after TAM treatment as in Fig. 3a (40–46 weeks of
age) was analyzed by flow cytometry. b The scheme of the Irf5 cKO combined with BZ-induced LLPC depletion; s.c. subcutaneously. c, d Irf5 and ISG
expression. Irf5 (c) and Oasl2 (d) mRNA levels in peripheral blood from Lyn−/−Irf5fl/fl (n= 11) and Lyn−/−Irf5fl/flCreER (n= 7) female and male mice
(29–32 weeks of age at week 0) treated as in b were analyzed by RT-qPCR. e The LLPC number in BM (left) and spleen (right) from WT (n= 8),
Lyn−/−Irf5fl/fl (n= 10), and Lyn−/−Irf5fl/flCreER (n= 6) mice at 12 weeks after the first injection (41–44 weeks of age) as in b was analyzed by flow
cytometry. f Spleen weight of mice in e. The circles and diamonds denote the female and male mice, respectively. g Autoantibody production. Serum anti-
dsDNA IgG from mice in c was quantified by ELISA. Data were pooled from two independent experiments. Horizontal bars (a, c–g) indicate mean ± SEM.
Dashed lines (c, d, g) denote mean data from WT mice (n= 5). *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided Student’s t test in a, e, f; two-sided paired
t test in c, d, g).
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autoantibody levels began to increase again, suggesting that the
remission was transient. Although continued administration of BZ
maintained the absence of the autoantibody, the total IgG level
declined below the normal level, which could lead to severe
adverse effects (Supplementary Fig. 9d).
Based on the above results, we next tested whether the
conditional deletion of Irf5 could restrain the disease flare, which
can occur after the transient remission induced by the brief BZ
treatment. Accordingly, we administered TAM in combination
with BZ to Lyn−/−Irf5fl/fl and Lyn−/−Irf5fl/flCreER mice (Fig. 4b).
The expression of Irf5 and ISG (Oasl2 and Ifit1) mRNAs in
peripheral blood quickly dropped in Lyn−/−Irf5fl/flCreER mice
(Fig. 4c, d and Supplementary Fig. 9e). Of note, data on
Lyn−/−Irf5fl/fl mice meant that the induction therapy alone
without Irf5 deletion did not suppress ISG expression; this finding
is reminiscent of human SLE patient data in the remission phase
(see Fig. 1). Bone marrow and spleen LLPC numbers returned to
the high level in Lyn−/−Irf5fl/fl mice 12 weeks after the BZ
administration, confirming the transient nature of the BZ-
induced LLPC depletion (Fig. 4e). On the other hand, when
IRF5 was conditionally deleted concomitantly with the induction
therapy, i.e., in TAM-treated Lyn−/−Irf5fl/flCreER mice, LLPC
numbers stayed at the levels comparable to those in WT mice.
Similar results were obtained regarding the spleen weight (Fig. 4f).
The serum anti-dsDNA autoantibody disappeared 2 weeks after
the BZ+ TAM treatment in both the Lyn−/−Irf5fl/fl strain and
Lyn−/−Irf5fl/flCreER strain (Fig. 4g). The autoantibody levels,
however, returned to the elevated values in the former strain
within several weeks, thus mimicking the recurrence. Strikingly,
this flare up of autoantibody production was remarkably weaker
in the latter strain, in which Irf5 was conditionally deleted. These
results indicated that the IRF5 inhibition indeed effectively
maintained the remission state in the mouse SLE model.
The development of an IRF5 inhibitor. The therapeutic effects
on the Lyn-deficient mouse SLE model obtained by the genetic
approach (deletion of Irf5 after the disease onset) next prompted
us to develop IRF5 inhibitors as novel therapeutics for SLE. We
performed high-throughput screening (HTS) of approximately
100,000 compounds to identify selective inhibitors of IRF5
transcriptional activity. One small-molecule compound, named
YE6144 (its chemical structure is presented in Fig. 5a), which was
obtained by analysis of analogs of an HTS hit compound, sub-
stantially inhibited the nuclear translocation of IRF5 in mono-
cytes and pDCs treated with R-848 (Fig. 5b). YE6144 inhibited
the phosphorylation of IRF5 in both human PBMCs and mouse
splenocytes (Fig. 5c). Because IRF5 and NF-κB are known to
share their upstream kinase IKKβ in the TLR-MyD88 pathway
(also see Fig. 1j and Supplementary Fig. 4b, c for data on the
IKKβ inhibitor TPCA-1), we next examined whether YE6144 also
inhibits NF-κB activation. Nuclear translocation of NF-κB,
however, turned out to be only marginally inhibited in monocytes
and was unchanged in pDCs (Fig. 5d). These findings suggested
that there exists a mechanism that discriminates between the
activation of IRF5 and that of NF-κB in these cell types. A recent
study reported that the endolysosomal transporter SLC15A4 and
the adaptor protein TASL mediate the selective recruitment and
activation of IRF5 by TLR7, TLR8, and TLR938. Although further
investigation and structural optimization are necessary to clarify
the detailed mechanism of action and to manufacture an agent for
clinical use, these results meant that the prototypical IRF5 inhi-
bitor YE6144 selectively suppresses IRF5 activity through inhi-
bition of IRF5 phosphorylation.
We next evaluated the effects of YE6144 on innate immune
responses mediated by TLR7 and TLR9, which are known to
participate in the SLE pathogenesis via the recognition of nucleic
acid-containing immune complexes39,40. Induction of type I IFN
genes, Ifnb1 and Ifna, in mouse splenocytes stimulated by TLR7
ligands [poly(U) or R-848] or TLR9 ligands (CpG-A or CpG-B
oligodeoxynucleotides [ODNs]) was remarkably weakened by the
YE6144 pretreatment (Fig. 5e). The production of IFN-β and
IFN-α in human PBMCs stimulated with R-848 was decreased by
the YE6144 pretreatment in a dose-dependent manner (Fig. 5f).
The half-maximal inhibitory concentration (IC50) of YE6144 for
inhibiting the production of these type I IFNs was approximately
0.09 μM. Essentially the same results were obtained in the analysis
of the induction of Il6, Tnf, and Il12b in mouse splenocytes and
the production of IL-6 and TNF in human PBMCs (Supplemen-
tary Fig. 10a, b).
An IRF5 inhibitor maintains disease remission in NZB/W F1
mice. We expected that our IRF5 inhibitor would suppress the
progression of mouse SLE, similar to the results obtained fol-
lowing the Irf5 conditional deletion in Lyn-deficient mice. Indeed,
the administration of YE6144 suppressed the exacerbation of
autoantibody production in NZB/W F1 mice, another mouse SLE
model, both before and after disease onset (Supplementary
Fig. 11a–d). Splenomegaly and renal dysfunction were also sup-
pressed by YE6144 treatment after disease onset (Supplementary
Fig. 11e–h). Unexpectedly, increases in CD80 on cDC2s, CD69
on CD4+ T cells, and the TMRM signals in Ly6C− monocytes
and pDCs in dimethyl sulfoxide (DMSO)-treated NZB/W F1
mice were not evident compared to WT C57BL/6 mice and
YE6144-treated NZB/W F1 mice (Supplementary Fig. 11i–k). We
infer that the mechanism of the disease in NZB/W F1 mice may
be somewhat distinct from the Lyn-deficient mouse model and
human SLE.
We further validated whether YE6144 administration main-
tains the remission in NZB/W F1 mice. BZ was administered two
or three times per week to NZB/W F1 mice until the serum anti-
dsDNA antibody level dropped below 1 μg/ml to induce
remission. After that, we administered YE6144 daily (Fig. 6a).
Just as in Lyn-deficient mice, the anti-dsDNA IgG production
depleted by BZ injection in NZB/W F1 mice recurred when the
vehicle (DMSO) was administered after BZ withdrawal (Fig. 6b).
In contrast, the YE6144 administration effectively maintained the
remission induced by BZ. Because it has been reported that
autoreactive LLPCs constitute a major population in the spleen of
NZB/W F1 mice41, we determined the number of splenic LLPCs
10 weeks after the administration of either DMSO or YE6144.
The number of LLPCs returned to the high level in the DMSO
group, but this elevation was significantly suppressed by YE6144
(Fig. 6c). Furthermore, other SLE symptoms such as splenome-
galy, proteinuria, glomerulonephritis, and aberrant ISG expres-
sion, which were seen in DMSO-treated NZB/W F1 mice, were all
effectively alleviated by YE6144 treatment of the mice (Fig. 6d–h
and Supplementary Fig. 11l, m). These data indicated that
IRF5 suppression by the prototypical small-molecule inhibitor
YE6144 indeed alleviated the disease course in the NZB/W F1
mouse model of SLE.
Taken together, our results on the two mouse SLE models,
Lyn-deficient and NZB/W F1 mice, prove that the post-disease
onset inhibition of IRF5 suppresses the disease course and is
especially effective in remission maintenance.
Discussion
In this study, we demonstrated that the excessive IRF5 activation
in patients with AP-SLE continues even in those with RP-SLE.
The degree of this persistent IRF5 hyperactivation positively
correlated with the serum levels of autoantibodies. Consistent
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with these findings, IRF5 activation was observed regardless of
the presence or absence of standard therapies. These results
suggest that the majority of current therapies for SLE are
incapable of relieving IRF5 hyperactivation. We can infer that the
persistent IRF5 hyperactivation in RP-SLE maintains a state of
disease “smoldering.” Although the patients with RP-SLE have
little or no overt clinical symptoms, IRF5 remains activated in
innate immune cells to evoke the production of cytokines, at least
a sufficient amount of type I IFNs to induce ISG expression and
possibly to promote OXPHOS in mitochondria. These “embers”
may lead to the production of residual autoantibodies often
detected in the remission phase. Then immune complexes form
and again activate IRF5 in innate immune cells, thereby setting up
a hidden vicious cycle. Although inflammation per se is restrained
by standard-of-care drugs such as glucocorticosteroids and
immunosuppressants, drug discontinuation, infection, or other
environmental factors may trigger the amplification of such an
IRF5-dependent vicious cycle, causing an SLE flare.
How does the small proportion of monocytes (the first and
third quartiles are 2.8 and 11%, respectively, in SLE patients), in
which IRF5 is hyperactivated, affect the disease pathogenesis? A
previous study has shown that the population of circulating
inflammatory CD5−CD163+CD14+ cells is expanded in SLE
patients and that they produce IFN-α and proinflammatory
cytokines when cultured with SLE serum42. In the present study,
our gating strategy to sort monocytes could not exclude this novel
cell type. Therefore, it is tempting to speculate that IRF5 is
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Fig. 5 Suppression of IRF5 and type I IFN by a prototypical IRF5 inhibitor YE6144. a Chemical structure of YE6144. b IRF5 NT in monocytes (Mo; left) or
pDCs (right) sorted from human HC PBMCs that were pretreated with the vehicle (DMSO) or 1 μM YE6144 for 30min and then were stimulated with 3
μM R-848 for 30min. c IRF5 phosphorylation. Human HC PBMCs and mouse WT splenocytes were pretreated with either 1 and 3 μM YE6144,
respectively, or DMSO for 30min and then stimulated with 3 μM R-848 for 60min. Cell lysates were analyzed by the capillary-based immunoassay with
antibodies against phospho-IRF5, total IRF5, and GAPDH as a loading control. d NF-κB p65 NT in cells in b. e, f Type I IFNs. eMouse WT splenocytes were
pretreated with either DMSO or YE6144 for 30min and next were stimulated with 2 μg/ml poly(U), 3 μM R-848, 1 μM CpG-A ODN, or 0.15 μM CpG-B
ODN for the indicated period. Total RNA was isolated, and the expression of Ifnb1 and Ifna (detection of 12 subtypes) was analyzed by RT-qPCR. f Human
HC PBMCs were pretreated with either DMSO (0) or YE6144 at the indicated doses for 30min and then were stimulated with 3 μM R-848 for 24 h. IFN-β
and IFN-α (detection of four subtypes) in culture supernatants was measured by ELISA. The concentration (0.03–10 μM) of YE6144 was plotted on a
logarithmic scale. The red line represents a four-parameter log-logistic dose–response curve. Data in b, d were compiled from three independent
experiments (n= 3 in total). Data in c, e, f are representative of two independent experiments (n= 3 in e and n= 3 [YE6144] or 6 [DMSO] in f for each
experiment). Horizontal bars (b, d–f) denote mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided Student’s t test).
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possibility is that most of the immune cells with activated IRF5
migrate to peripheral tissues; hence, the proportion of cells with
activated IRF5 appears to be small in peripheral blood.
By means of mouse SLE models, this study addressed the
therapeutic implications of IRF5 targeting. IRF5 downregulation
was quite effective, whereas IFNAR1 downregulation was insuf-
ficient for suppressing the SLE-like disease in Lyn-deficient mice.
The recent clinical trial of the IFNAR1 antagonist antibody ani-
frolumab showed a statistically significant reduction in disease
activity versus a placebo in SLE patients14. Nevertheless, the
reduction was not dramatic, and besides, a considerable rate of
relapse was observed. Our results indicate that inhibition of IRF5
may solve this problem. We showed that IRF5 is involved in the
induction of not only ISG but also OXPHOS genes and mito-
chondrial activity in SLE pathogenesis. It has been shown that
mitochondrial hyperpolarization induces the production of
reactive oxygen species (ROS)43. Dysfunctional mitochondria
with excessive ROS levels are prone to extrude mitochondrial
DNA into the cytoplasm to stimulate the TLR9, cGAS-STING, or
inflammasome pathway44. Therefore, we envisage that IRF5-
mediated mitochondrial dysfunction might promote the vicious
cycle of SLE, in which immune complexes containing auto-
antibodies and nucleic acids stimulate multiple types of cells and
induce cytokines that further activate immune cells1–3,21. It will
be an interesting future challenge to explore the direct target
genes of IRF5 in the relevant cell types, for example, monocytes,
pDCs, and the aforementioned CD5−CD163+CD14+ cells.
The conditional Irf5 deletion in diseased Lyn-deficient mice
not only abrogated ISG expression but also completely inhibited
the elevation of the serum anti-dsDNA antibody level, indicating
that the formation of new autoreactive plasma cells is suppressed,
even though the cause of the disease, i.e., Lyn deficiency, persists.
It would be worth mentioning that a recent study suggests that
autoantibody-secreting plasma cells are generated from CD11c
+T-bet+ B cells in a manner dependent on TLR7 signaling45,
which is known to involve IRF5. In fact, IRF5 is reported to be
required for the formation of age-associated B cells, a sub-
population of CD11c+T-bet+ B cells26. On the other hand, the
a
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Fig. 6 Maintenance of remission by YE6144 in the NZB/W F1 mouse model of SLE. a The scheme of YE6144 treatment combined with BZ administration
b Autoantibody production. Serum anti-dsDNA IgG levels in NZB/W F1 female mice (31–34 weeks of age at week 0) treated with either DMSO (n= 13) or
YE6144 (n= 12) after BZ injection were analyzed by ELISA. The dashed line denotes the mean data from untreated WT C57BL/6 (B6) mice (n= 3). c The
LLPC number in the spleen from WT B6 mice (n= 8) and NZB/W F1 mice in b at 10 weeks after the initial YE6144 injection (age 41–44 weeks) was
analyzed by flow cytometry. d Spleen weight of mice in c. e The proteinuria score of WT B6 mice (n= 10) and NZB/W F1 mice in c. f, g Kidney pathology of
mice in c analyzed as in Fig. 2d, e. Representative images are shown and scale bars correspond to 20 μm (f). h ISG expression. The Ifit1 mRNA level in
peripheral blood from WT B6 mice (n= 5) and NZB/W F1 mice in c was analyzed by RT-qPCR. Data were compiled from three independent experiments.
Horizontal bars represent mean ± SEM (b–d, g, h) or median (e). **P < 0.01, ***P < 0.001 (two-sided paired t test in b [the same treatment samples]; two-
sided Student’s t test in b [different treatment samples], c, d, g, h; and two-sided Mann–Whitney U test in e).
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conditional Irf5 deletion was unable to reduce the serum auto-
antibody concentration to the level below that observed at the
start of Irf5 deletion, probably owing to the presence of LLPCs.
Nevertheless, both the conditional deletion of Irf5 in Lyn-
deficient mice and the administration of the newly identified
prototypical IRF5 inhibitor in NZB/W F1 mice revealed that,
once LLPCs are depleted by BZ, the IRF5 inhibition can effec-
tively maintain the remission, again, despite the persistence of
disease causes. LLPCs are nondividing cells and thus thought to
be resistant to glucocorticoids and antiproliferative agents35,36. A
candidate drug (other than BZ) for the elimination of LLPCs
would be atacicept, which inhibits the binding of BAFF and a
proliferation-inducing ligand to their receptors including B-cell
maturation antigen (BCMA), because plasma cell survival is
impaired in BCMA-deficient mice46. Although a long-term
(52 weeks) clinical trial of atacicept in SLE has been dis-
continued due to severe adverse effects47, another clinical trial
(short term, 24 weeks) has shown its efficacy without increased
risk of severe adverse events48, suggesting that atacicept is useful
for short-term treatment.
Considering our findings in the analyses of SLE patients’
samples and mouse SLE models, we envision a novel therapy for
SLE using an IRF5 inhibitor as follows. First, IRF5 activation
status of PBMCs from SLE patients is assessed as a companion
diagnostic method of the IRF5 inhibitor therapy. The patients
who display hyperactivation of IRF5 will be referred to the
combination treatment with standard remission induction
therapies and an IRF5 inhibitor. A long-term remission induced
by the IRF5 inhibitor together with standard drugs may even-
tually result in the disappearance of LLPCs and autoantibodies. If
the autoantibody levels remain high, then anti-LLPC drugs such
as BZ or atacicept are administered for a short period to induce a
deep remission. Eventually, the combination therapy is replaced
by IRF5 inhibitor monotherapy for remission maintenance. A
recent study reported the efficacy of targeting IRF5 in SLE model
mice using a cell-permeable peptide inhibitor49, which corrobo-
rates our current results. In conclusion, our findings suggest that
the inhibition of IRF5 may overcome the limitations of current
SLE therapies and thereby facilitate drug discovery research on
IRF5 inhibitors.
Methods
Biological samples from humans. The research on human donors conducted in
this study was approved by the Yokohama City University Certified Institutional
Review Board (approval No. A120322001). Informed consent was obtained from all
donors or their legal guardians. Peripheral blood from 58 Asian pediatric or adult
patients with SLE was obtained at Yokohama City University Hospital. Each
patient met at least four of the American College of Rheumatology 1997 revised
classification criteria50. Peripheral blood from 25 healthy donors was obtained too.
Both the SLE patients and healthy donors participated voluntarily in this study. To
prevent degradation or modification of the IRF5 protein, protease inhibitor dii-
sopropyl fluorophosphate (Wako) and phosphatase inhibitors cypermethrin
(Abcam) and okadaic acid (Santa Cruz Biotechnology) were added into hepar-
inized peripheral blood shortly after blood sampling. Serum was separated from
peripheral blood, which was stored at −80 °C until the analysis. PBMCs were
isolated using Lymphoprep and SepMate-50 (STEMCELL Technologies) mostly
according to the manufacturer’s instructions, except that the first centrifugation
lasted 20 min and all centrifugation steps were carried out at 4 °C to avoid
degradation of IRF5. Total RNA from peripheral blood stabilized in PAXgene
Blood RNA Tubes (BD Biosciences) was purified using the PAXgene Blood miRNA
Kit (Qiagen, Cat. No. 763134) according to the manufacturers’ protocols. Blood test
results and clinical data were utilized to calculate disease activity by means of the
SLEDAI. AP-SLE and RP-SLE in the patients were defined as the SLEDAI-2K of ≥5
and <5, respectively.
Mouse biological samples. All animal experiments were conducted in accordance
with Guidelines for the Proper Conduct of Animal Experiments (Science Council
of Japan), and all protocols were approved by the institutional review boards of
Yokohama City University (protocol Nos. F-A-17-018 and F-A-20-043). Lyn−/−,
Irf5−/−, Ifnar1−/−, and Lyn−/−Irf5+/− and Lyn−/−Irf5−/− mice on a C57BL/6
background have been described previously20,25,51,52. WT (C57BL/6JJcl) and NZB/
W F1 (NZBWF1/Slc) mice were purchased from CLEA Japan and Japan SLC,
respectively. Irf5fl/fl mice (C57BL/6-Irf5tm1Ppr/J; stock No. 017311) and CreER mice
(B6.Cg-Tg[CAG-cre/Esr1*]5Amc/J; stock No. 004682) were purchased from The
Jackson Laboratory. Lyn−/−Ifnar1+/−, Lyn−/−Ifnar1−/−, Lyn−/−Irf5fl/fl, and
Lyn−/−Irf5fl/flCreER mice on a C57BL/6 background were generated through
crossing of appropriate strains. Mice were housed in a 12-h/12-h light/dark cycle at
24.0 ± 1.0 °C and a humidity range of 50.0 ± 5.0%. Mouse splenocytes were pre-
pared from a spleen followed by red blood cell (RBC) lysis with ammonium
chloride–potassium (ACK) buffer. In case of other than flow cytometric analysis of
LLPCs, the spleen was incubated with 1.67 U/ml Liberase DL (Roche) and 0.2 mg/
ml DNase I (Roche) for 30 min at 37 °C, prior to RBC lysis. Bone marrow cells were
obtained by flushing the femur and tibia, followed by RBC lysis with ACK buffer.
Total RNA from peripheral blood stabilized in RNAprotect Animal Blood Tubes
(Qiagen) was purified with the RNeasy Protect Animal Blood Kit (Qiagen, Cat. No.
73224) and that from splenocytes using NucleoSpin RNA (Takara, Cat. No.
U0955C). Proteinuria was tested by means of Albustix (Siemens). Serum blood
urea nitrogen (BUN) levels were quantified via a colorimetric method using a BUN
Detection Kit (Arbor assays, Cat. No. K024-H1).
Reagents. Mycophenolic acid, the active moiety of MMF, was purchased from
Tokyo Chemical Industry. PSL, HCQ, and TPCA-1 were bought from Sigma-
Aldrich. Poly(U) (InvivoGen) was complexed with the DOTAP Liposomal
Transfection Reagent (Roche) at a ratio of 1 μg of poly(U) per 6 μl of DOTAP and
was used for stimulation. R-848 (resiquimod) was acquired from Enzo Life Sci-
ences. CpG-B ODN 1668 (5′-T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*T*G*
C*T-3′) and CpG-A ODN 2216 (5′-G*G*GGGACGATCGTCG*G*G*G*G*G-3′)
were synthesized by Eurofins Genomics (an asterisk indicates a phosphorothioate
linkage). The monoclonal antibody that specifically recognizes phosphorylated
IRF5 (anti-phospho-IRF5 antibody) was generated by the antibody phage display
method53 following the immunization of rabbits with a synthetic peptide corre-
sponding to the region around phosphorylated serine 446 (S446) of human IRF5
isoform B (equivalent to the S462 of human IRF5 isoform D).
A quantitative assay of nuclear translocation of transcription factors. PBMCs
(1–5 × 106) were stained with fluorescently labeled antibodies to cell surface mar-
kers: CD123, CD14, CD141, CD19, CD1c, and CD303 (the fluorochromes, clones,
and vendors are listed in Supplementary Table 2). Dead cells were stained with
Zombie Red (BioLegend). Cells were then fixed in Cytofix fixation buffer (BD
Biosciences) for 10 min at 37 °C and permeabilized with Perm buffer III (BD
Biosciences) for 30 min on ice. After washing, the cells were stained with an anti-
IRF5 (ab21689; Abcam) or anti-NF-κB p65 (sc372-X; Santa Cruz Biotechnology)
rabbit polyclonal antibody. Normal rabbit IgG (Cell Signaling Technology) served
for control staining. Then the cells were stained with an Alexa Fluor 488 (AF488)-
conjugated anti-rabbit F(ab′)2 fragment (Jackson ImmunoResearch Laboratories) as
a secondary antibody together with a phycoerythrin (PE)-cyanine 7 (Cy7)-con-
jugated anti-HLA-DR antibody (clone L243, BioLegend). Subsequently, monocytes
(CD14+CD19−), B cells (CD14−CD19+), cDCs (CD14−CD19−CD123−HLA-DR+
CD1c+CD141−), and pDCs (CD14−CD19−CD123+HLA-DR+CD303+) were
sorted out on a FACSAria II instrument (BD Biosciences) with a 100-μm nozzle in
4-way purity mode, using the FACS DIVA software. Nuclei of the sorted cells were
stained with 4′,6-diamidino-2-phenylindole (DAPI) Fluoromount-G (Southern
Biotech), and next, the cells were transferred into a 384-well glass bottom plate
(Greiner) and centrifuged at 400 × g for 5 min. Fluorescent images were obtained on
an FV1000-D confocal laser scanning microscope (Olympus) using the FV-10 ASW
software. The images were analyzed in Cellprofiler54. AF488 signal images were
merged with the corresponding DAPI signal images to distinguish nuclear and
cytosolic AF488 signals (see Supplementary Fig. 1) to obtain the nuclear/cytosolic
mean fluorescence intensity (MFI) ratio. IRF5 was judged to be translocated into the
nucleus when the nuclear/cytosolic MFI ratio in the cell was greater than 1.5-fold of
the most frequent ratio from the same sample containing 75–100 cells. The total
strength of aberrant IRF5 nuclear translocation was calculated by summing the IRF5
nuclear/cytosolic MFI ratios exceeding 1.5-fold of the most frequent ratio. Note that
the most frequent IRF5 nuclear/cytosolic MFI ratios between healthy donors and
SLE patients were very comparable: 0.58 ± 0.07 and 0.58 ± 0.06 in monocytes, 0.62
± 0.19 and 0.59 ± 0.12 in pDCs, 0.55 ± 0.10 and 0.56 ± 0.07 in cDCs, and 0.62 ± 0.13
and 0.60 ± 0.11 in B cells, respectively (mean ± SD).
Reverse transcription quantitative PCR (RT-qPCR). Total RNA was reverse-
transcribed using the PrimeScript RT Reagent Kit (Takara, Cat. No. RR037B) or
the PrimeScript II 1st Strand cDNA Synthesis Kit (Takara, Cat. No. 6210 A)
according to the manufacturer’s instructions. The cDNA was mixed with the
Thunderbird SYBR qPCR Mix (Toyobo, Cat. No. QPS-201) and subjected to RT-
qPCR on a CFX96 Real-Time System (Bio-Rad) using the CFX Manager software.
As per the manufacturer’s instructions, a typical two-step PCR protocol was per-
formed (1 min at 95 °C followed by 40 cycles of 15 s at 95 °C and 45 s at 60 °C).
Gene-specific primers designed by means of Primer-BLAST (NCBI) are listed in
Supplementary Table 3. The data were analyzed by the ΔΔCT method and nor-
malized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Gapdh, or Rps29
expression levels.
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In vitro treatment of human PBMCs and mouse splenocytes. Cells were
resuspended at 2 × 106 (human PBMCs) or 4 × 106 (mouse splenocytes) cells/ml in
R10 medium (RPMI 1640 medium [Nacalai Tesque] supplemented with 10% heat-
inactivated fetal bovine serum [FBS; Equitech-Bio], 1 mM non-essential amino
acids [Thermo Fisher Scientific], 1 mM sodium pyruvate [Thermo Fisher Scien-
tific], 50 μM 2-mercaptoethanol [Sigma-Aldrich], 100 U/ml penicillin [Meiji], and
100 μg/ml streptomycin [Meiji]) and were seeded in tissue culture plates. Thirty
minutes after the inoculation, the cells were pretreated with an appropriate reagent
and then stimulated with a TLR ligand. The dose and time of each treatment are
given in the figure legends.
Capillary-based immunoassay. Cells were lysed in RIPA buffer (50 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 0.5% of sodium
deoxycholate, and 1% NP-40) supplemented with the cOmplete EDTA free pro-
tease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail
(Roche). The cell lysates were centrifuged, and the supernatants were subjected to
the automated capillary-based immunoassay on a Wes Simple Western System
(ProteinSimple) using the Compass software. Anti-IRF5 antibody (clone
EPR17067; Abcam), anti-IKKβ antibody (2678 S; CST), and anti-GAPDH antibody
(clone 6C5; Abcam) were diluted to concentrations of 25, 1.9, and 10 μg/ml,
respectively, with antibody diluent 2 (ProteinSimple). The anti-phospho-IRF5
antibody was diluted to 25 μg/ml with 5% skim milk in Tris-buffered saline con-
taining 0.05% Tween 20. A horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG antibody (ProteinSimple) or anti-mouse IgG antibody (Millipore) served as a
secondary antibody. Lumino-S/peroxidase (for total IRF5, IKKβ, and GAPDH;
ProteinSimple) or Immunostar LD (for phospho-IRF5; Wako) were used as sub-
strates for HRP.
Plasmids. The constructs pcDNA3.1-IRF5(isoform B), pcDNA3.1-IRF5(S446A),
and pcDNA3.1-IKKβ have been described previously25. The cDNA of human IRF5
isoform D (RefSeq accession no. NM_001098629) was obtained by RT-PCR from
healthy donor PBMC RNA. The pcDNA3.1-IRF5(isoform D) plasmid was con-
structed by inserting IRF5 cDNA into the pcDNA3.1(−) vector. Using poly-
ethylenimine (Polysciences), HEK293T cells were co-transfected with empty
pcDNA3.1(−), pcDNA3.1-IRF5 (WT isoform B, S446A isoform B, or WT isoform
D), and/or pcDNA3.1-IKKβ. Twenty-four hours after transfection, the cells were
subjected to a capillary-based immunoassay.
Enzyme-linked immunosorbent assay (ELISA). Anti-dsDNA antibodies and
immunoglobulin in mouse serum samples or cytokines in human PBMC culture
supernatants were measured by ELISA. For anti-dsDNA IgG analysis, F96 Max-
iSorp Nunc-immuno plates (Thermo Fisher Scientific) at 4 °C were coated over-
night with 0.05% protamine sulfate (Sigma-Aldrich) and 50 µg/ml calf thymus
DNA (Nacalai Tesque) diluted in phosphate-buffered saline (PBS). The plates were
washed four times with 0.05% Tween 20 in PBS (PBST) and then incubated with
blocking buffer (1% bovine serum albumin [BSA] in PBST) at 20–25 °C for 1 h
with shaking. An anti-dsDNA mouse monoclonal IgG2a antibody (clone HYB331-
01; Santa Cruz Biotechnology) served as a standard. After the plates were washed
with PBST four times, serum samples diluted to 1:1000 with blocking buffer and
the standard dsDNA antibody serially diluted with blocking buffer were added and
incubated at 20–25 °C for 1 h with shaking. The plates were then washed four times
and were incubated for 1 h at 20–25 °C with an HRP-conjugated goat anti-mouse
IgG Fc fragment (Bethyl Laboratories) diluted to 1:20,000 with 1% BSA in PBST.
After four washes, the tetramethyl benzidine substrate (TMB Substrate Set; Bio-
Legend) was added into wells of the plates, and absorbance data at 450/595 nm
were recorded on a Sunrise absorbance reader (TECAN). Serum levels of total IgG,
IgG1, and IgG2c were determined using ELISA kits purchased from Bethyl
Laboratories (Cat. Nos. E90-131, E90-105, and E90-136, respectively). PBMC
culture supernatants were analyzed with LumiKine Xpress hIFN-α 2.0 (InvivoGen,
Cat. No. luex-hifnav2), Human IFN-beta DuoSet (R&D Systems, Cat. No. DY814-
05), Human IL-6 ELISA MAX Standard Sets (BioLegend, Cat. No. 430501), and
Human TNF-α ELISA MAX Standard Sets (BioLegend, Cat. No. 430201)
ELISA kits.
Mouse kidney pathology and IgG deposition. Kidneys freshly excised from mice
were either fixed in a neutral buffered 10% formalin solution (Wako) for 2–6 days
or snap-frozen in the Tissue-Tek OCT compound (Sakura Finetek Japan) using
liquid nitrogen. Formalin-fixed kidneys were embedded in paraffin by means of a
closed self-locking embedding device, Tissue-Tek VIP5 Jr. (Sakura Finetek Japan).
Freshly frozen blocks were stored at −80 °C until cryosection preparation. Paraffin-
embedded kidneys were sectioned and stained with hematoxylin and eosin (H&E)
or periodic acid-Schiff reagents by Tokushima Molecular Pathology Institute. The
images of stained kidney sections were obtained using Biozero BZ-8000 (Keyence)
and BZ Viewer software. Glomerular cellularity was assessed by calculating the
mean number of nuclei in ten glomeruli from the H&E-stained cross-sections per
mouse using the ImageJ software (NIH)55. IgG deposition in glomeruli was
assessed by immunofluorescent staining of 4 µm kidney cryosections prepared on a
cryostat. Cryosections mounted on Superfrost slide glass (Matsunami) were
immediately fixed in −80 °C acetone for 30 s, rinsed in PBS, and blocked with PBS
containing 5% skim milk (Morinaga) at 20–25 °C for 30 min. The sections were
then incubated with biotinylated anti-mouse IgG (Vector Laboratories) in blocking
buffer at 4 °C overnight. After that, the sections were washed three times with PBS
and stained with AF488-conjugated streptavidin (Life Technologies) and then with
Hoechst 33342 (Life Technologies). After a rinse with PBS, the sections were
mounted with the Prolong Gold Antifade Reagent (Invitrogen). Fluorescent images
were scanned by means of FV1000-D. The MFI of each glomerulus was calculated
using the ImageJ software and the MFI of five glomeruli were averaged. The relative
MFI was determined as the average MFI normalized to the average MFI in the WT
samples.
RNA sequencing and bioinformatics analysis. Total RNA from peripheral blood
was prepared for five mice of each of the following mouse strains: WT, Lyn−/−,
Lyn−/−Ifnar1−/−, Lyn−/−Irf5+/−, and Lyn−/−Irf5−/−. The RNA samples were
quantified on a nanophotometer (Implen), and their quality was assessed using the
Agilent RNA6000 Pico Kit (Cat. No. 5067-1513) and Bioanalyzer in accordance
with the manufacturers’ instructions. All samples had an RNA integrity number
>7.2. Libraries were prepared from 500 ng of total RNA by means of SureSelect
Strand-Specific RNA Library Prep for Illumina Multiplexed Sequencing (Agilent
Technologies). The size of final cDNA libraries was validated using the Agilent
High Sensitivity DNA Kit (Cat. No. 5067-4626) and Bioanalyzer in line with the
manufacturer’s instructions. Concentrations of individual libraries were validated
by qPCR with the KAPA Library Quantification Kit (Nippon Genetics, Cat. No.
KK4824). Pooled libraries were subjected to the sequencing using the Illumina
NextSeq 500/550 High Output Kit v2 (Cat. No. 20024906) and NextSeq 500 Sys-
tem. Illumina Real-Time Analysis software was used for base calling. All sequenced
reads were converted to FASTQ format in the bcl2fastq software, followed by
mapping to the mouse genome reference sequence mm10 using STAR56. Raw read
counts were obtained in featureCounts57. After normalization to the trimmed
mean of M values by the calcNormFactors function in edgeR58, final read counts
were obtained by the rpkm function. GSEA was performed as described
elsewhere59 using the hallmark gene sets60.
In vivo treatments of mice. TAM (Sigma-Aldrich) was dissolved at 100 mg/ml in
99.5% ethanol, and the aliquots were stocked at −20 °C. Prior to administration,
the aliquots were further diluted with corn oil (Sigma-Aldrich) and then admi-
nistered to mice by oral gavage (2 mg/250 μl/mouse, once a day for 5 days). BZ
(Wako) was dissolved at 20 mg/ml in DMSO, stocked at −20 °C, diluted with PBS,
and injected subcutaneously at a dose of 0.75 mg/(kg body weight) in accordance
with the treatment scheme described in the figures. YE6144 was dissolved in PBS
containing 10% DMSO and subcutaneously administered daily to NZB/W F1 mice
at a dose of 40.0 mg/(kg body weight).
Flow cytometry. The mouse splenocytes and bone marrow cells were preincubated
with anti-mouse CD16/CD32 (BioLegend) antibody to block Fcγ receptors and
then stained with the antibodies (Supplementary Table 2) in 2% FBS at 4 °C for 30
min. To measure the mitochondrial membrane potential, stained cells were incu-
bated with 50 nM TMRM (Thermo Fisher Scientific) in R10 medium at 37 °C for
30 min. The TMRM fluorescence was detected using the PE channel. Dead cells
were stained with 7-aminoactinomycin D for 5 min. Data were acquired on BD
FACSCanto II (BD Biosciences) using the FACS DIVA software and analyzed in
the FlowJo software (Tree Star).
Screening of IRF5 inhibitors. A reporter system that distinguishes the tran-
scriptional activities of IRF5 and NF-κB was established and used for HTS. A
library containing ~100,000 compounds was subjected to the screening via the
reporter system to identify the compounds that selectively inhibit IRF5 tran-
scriptional activity, thereby yielding 26 small-molecule hit compounds. Ten of
these hit compounds were validated by endogenous gene expression analysis. One
of the validated hit compounds strongly inhibited IRF5 activation at a dose much
different from its toxic dose. After that, several analogs of the confirmed hit
compound were assessed. One of these compounds, YE6144, was found to have
better photoisomerization properties and less toxicity in vivo.
Statistical analysis. All statistical analyses were performed in the R software. For a
comparison of non-normally distributed data, Mann–Whitney U test was carried
out. For a comparison of normally distributed data, either Student’s t test or
Welch’s t test was conducted. For a paired comparison of data, paired t test was
performed. For correlation analysis, Spearman’s rank-ordered correlation was
utilized. Data with P values < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA sequencing (RNA-seq) data have been deposited in the Gene Expression
Omnibus (GEO) database with the primary accession code GSE146334. The public RNA-
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24609-4
12 NATURE COMMUNICATIONS |         (2021) 12:4379 | https://doi.org/10.1038/s41467-021-24609-4 | www.nature.com/naturecommunications
seq data from SLE patients and healthy donors31 were retrieved from the GEO database
with the primary accession code GSE72509. Source data are provided with this paper.
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